Pipeline Therapeutics’ PIPE-505 for acute sensorineural hearing loss had its Phase Transition Success Rate (PTSR) jump nine points to 56% after completing its Phase I/IIa trial. The PTSR change occurred on 25 June after the trial’s ClinicalTrials.gov listing was updated as completed on 23 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The San Diego, California-based company enrolled 28 patients in the Phase I/IIa trial (NCT04462198), which was four patients higher than planned, as per its ClinicalTrials.gov listing. Patients were randomized to either receive an intratympanic dose of PIPE-505 or placebo, with safety as the primary endpoint.

PIPE-505 is a gamma secretase inhibitor that targets two pathways associated with sensorineural hearing loss and audibility. Previously, Pipeline completed a USD 80m Series C raise for the development of this asset as well as for its multiple sclerosis asset PIPE-307, according to an 11 February press release.

The completed Phase I/IIa also led to a modest 1-point bump on PIPE-505’s Likelihood of Approval (LoA), which rose to 2%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Manasi Vaidya is a Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.